Selected transactions
Deal Type
Advisor to Bridgepoint in the acquisition of a majority stake in Laboratoire Vivacy SA.
Financial Advisor to Bridgepoint in divesting a majority in HTL Biotech, a pharmaceutical-grade Hyaluronic Acid (Hyaluronan) and other Glycosaminoglycans (GAGs) and other functional Biopolymers such as PDRN or Polynucleotides (PN) to Montagu.
Divestiture to AbbVie-Allergan Aesthetics for an undisclosed purchase price. Transferred brands include Crystalys, HArmonyCa, Hydryalix and Hydryal, Composite Matrix Dermal Fillers based on CAHA.
Exclusive Financial Advisor to Nicox for the sale of the remaining stake in VISUfarma to GHO Capital.
Exclusive Financial Advisor to the Largest Polish Medical Aesthetic Group for the Divestiture of a 51% stake to Abris Capital, a Polish Growth Capital PE Fund and concurrent Entry into a Shareholders’ Agreement.
Exclusive Financial Advisor in the Divestiture to the of Sothys SA’s 66.67% stake in Simone Mahler, the French dermo-cosmetic player operating a network of Natural Health Beauty Spas (« Instituts Mahler »), to Simone Mahler’s Management.
Exclusive Financial Advisor to Bloomage for the payment structure aligned with future financial performance.
Exclusive Financial Advisor to Nicox for the Transfer of its European commercial operations to a newly-founded company focused on ophthalmic products in Europe.
Exclusive Financial Advisor to Delife Srl and Relivia Srl on their sale to A. Menarini Industrie Farmaceutiche Riunite Srl.
Exclusive Financial Advisor to Bloomage for the completion of a strategic partnership and investment of 33.4% in Laboratoires Vivacy.
Exclusive Financial Advisor in the acquisition of the outstanding equity of Aciex Therapeutics, Inc., a private, US-based, ophthalmic development pharmaceutical company.
Exclusive Financial Advisor to NicOx SA on the acquisition of Laboratoires Doliage and concurrent entry into ancillary agreements with the Seller.